BioSpace News Archive

TC BioPharm PLC a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, announced that the company will host a shareholder update call on Tuesday, March 5th, 2024, at 4:30 p.m. ET.

LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”) today announced that René Bernards, PhD, professor of molecular carcinogenesis at Utrecht University in Amsterdam and head of molecular carcinogenesis at the Netherlands Cancer Institute, will present new pre-clinical data on LIXTE’s lead compound, LB-100, at the Joint Conference of European and American Associations for Cancer Research this week in Dublin, Ireland.

Evolus, Inc. today announced that members of its management team will present at the following investor conferences in March.

On February 8, 2024, The Speak Foundation, a patient-led 501(c)(3) organization for Limb-Girdle Muscular Dystrophy (LGMD), convened a multi-stakeholder LGMD Scientific Workshop in Rockville, Maryland.

Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced the reappointment of Cintia Piccina as Chief Commercial

Alzheon, Inc. announced its participation in the upcoming International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders in Lisbon, Portugal from March 5–9, 2024.

Tarsus Pharmaceuticals, Inc. announced financial results for the fourth quarter and full-year ended December 31, 2023, and recent business achievements.

Nuvalent, Inc. announced that the U.S. Food and Drug Administration has granted breakthrough therapy designation to NVL-520 for the treatment of patients with ROS1-positive metastatic non-small cell lung cancer who have been previously treated with two or more ROS1 tyrosine kinase inhibitors.

BrainStorm Cell Therapeutics Inc. announced that it will present a poster outlining the proposed design for a Phase 3b trial of NurOwn® in amyotrophic lateral sclerosis at the MDA Clinical and Scientific Conference, on Monday, March 4 between 6-8 p.m. at the Hilton Orlando Hotel, Florida.

Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, highlighted pipeline progress, reiterated key anticipated milestones and reported fourth quarter and full year 2023 financial results.